Efficacy and Safety of VX-659-102 Combination Therapy in Subjects iwth Cystic Fibrosis who are heterozygous for F508del Mutation & minimal function mutation

Administered By

Awarded By

Contributors

Start/End

  • June 5, 2018 - June 14, 2019